CD21-/low marginal zone B cells highly express Fc receptor-like 5 protein and are killed by anti-Fc receptor-like 5 immunotoxins in hepatitis C virus-associated mixed cryoglobulinemia vasculitis

Arthritis and Rheumatology

Volumn 66, Issue 2, 2014, Pages 433-443

  Terrier, Benjamin ^a   Nagata, Satoshi ^b   Ise, Tomoko ^b   Rosenzwajg, Michelle ^c   Pastan, Ira ^d   Klatzmann, David ^c   Saadoun, David ^a   Cacoub, Patrice ^a  

^a CNRS   (France)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c INSERM   (France)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; FC RECEPTOR; FC RECEPTOR LIKE PROTEIN 1; FC RECEPTOR LIKE PROTEIN 2; FC RECEPTOR LIKE PROTEIN 3; FC RECEPTOR LIKE PROTEIN 4; FC RECEPTOR LIKE PROTEIN 5; FC RECEPTOR LIKE PROTEIN 5 ANTIBODY; IMMUNOTOXIN; PEPTIDES AND PROTEINS; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOGLOBULINEMIA; CYTOTOXICITY; FEMALE; HEPATITIS C VIRUS; HEPATITIS C VIRUS ASSOCIATED MIXED CRYOGLOBULINEMIA VASCULITIS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MALE; MIDDLE AGED; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; VASCULITIS;

ADULT; AGED; APOPTOSIS; B-LYMPHOCYTES; CASE-CONTROL STUDIES; COMORBIDITY; CRYOGLOBULINEMIA; EXOTOXINS; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOTOXINS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PSEUDOMONAS; RECEPTORS, CELL SURFACE; RECEPTORS, COMPLEMENT 3D; RECEPTORS, IMMUNOLOGIC; VASCULITIS;

EID: 84896273109     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38222     Document Type: Article

References (43)

1. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327: 1490-5.
2. Hermine O, Lefrere F, Bronowicki JP, Mariette X, Jondeau K, Eclache-Saudreau V, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347: 89-94.
3. Saadoun D, Suarez F, Lefrere F, Valensi F, Mariette X, Aouba A, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005;105: 74-6.
4. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 1995;90: 548-52.
5. Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160: 3594-601.
6. Racanelli V, Sansonno D, Piccoli C, D'Amore FP, Tucci FA, Dammacco F. Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients. J Immunol 2001;167: 21-9.
7. Vallat L, Benhamou Y, Gutierrez M, Ghillani P, Hercher C, Thibault V, et al. Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection. Arthritis Rheum 2004;50: 3668-78.
8. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998;91: 2433-42.
9. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, et al. Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factorproducing cells that occur mainly in type II cryoglobulinemia. Blood 2000;96: 3578-84.
10. Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005;174: 6532-9.
11. Charles ED, Green RM, Marukian S, Talal AH, Lake-Bakaar GV, Jacobson IM, et al. Clonal expansion of immunoglobulin M-CD27- B cells in HCV-associated mixed cryoglobulinemia. Blood 2008;111: 1344-56.
12. Knight GB, Gao L, Gragnani L, Elfahal MM, De Rosa FG, Gordon FD, et al. Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies. Arthritis Rheum 2010;62: 2152-9.
13. Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011;117: 5425-37.
14. Terrier B, Joly F, Vazquez T, Benech P, Rosenzwajg M, Carpentier W, et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 2011;187: 6550-63.
15. Isnardi I, Ng YS, Menard L, Meyers G, Saadoun D, Srdanovic I, et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010;115: 5026-36.
16. Maltais LJ, Lovering RC, Taranin AV, Colonna M, Ravetch JV, Dalla-Favera R, et al. New nomenclature for Fc receptor-like molecules. Nat Immunol 2006;7: 431-2.
17. Ehrhardt GR, Cooper MD. Immunoregulatory roles for Fc receptor- like molecules. Curr Top Microbiol Immunol 2011;350: 89-104.
18. Davis RS. Fc receptor-like molecules. Annu Rev Immunol 2007; 25: 525-60.
19. Haga CL, Ehrhardt GR, Boohaker RJ, Davis RS, Cooper MD. Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci U S A 2007;104: 9770-5.
20. Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD. FcRH1: an activation coreceptor on human B cells. Blood 2005;105: 1121-6.
21. Jackson TA, Haga CL, Ehrhardt GR, Davis RS, Cooper MD. FcR-like 2 inhibition of B cell receptor-mediated activation of B cells. J Immunol 2010;185: 7405-12.
22. Kochi Y, Myouzen K, Yamada R, Suzuki A, Kurosaki T, Nakamura Y, et al. FCRL3, an autoimmune susceptibility gene, has inhibitory potential on B-cell receptor-mediated signaling. J Immunol 2009;183: 5502-10.
23. Ehrhardt GR, Davis RS, Hsu JT, Leu CM, Ehrhardt A, Cooper MD. The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci U S A 2003;100: 13489-94.
24. Schreeder DM, Cannon JP, Wu J, Li R, Shakhmatov MA, Davis RS. FcR-like 6 is an MHC class II receptor. J Immunol 2010;185: 23-7.
25. Wilson TJ, Fuchs A, Colonna M. Human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol 2012;188: 4741-5.
26. Dement-Brown J, Newton CS, Ise T, Damdinsuren B, Nagata S, Tolnay M. Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes. J Leukoc Biol 2012;91: 59-67.
27. Franco A, Damdinsuren B, Ise T, Dement-Brown J, Li H, Nagata S, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol 2013;190: 5739-46.
28. Zhu Z, Li R, Li H, Zhou T, Davis RS. FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling. Proc Natl Acad Sci U S A 2013;110:E1282-90.
29. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 2007;21: 169-74.
30. Elkins K, Zheng B, Go M, Slaga D, Du C, Scales SJ, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther 2012;11: 2222-32.
31. Ise T, Maeda H, Santora K, Xiang L, Kreitman RJ, Pastan I, et al. Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res 2005; 11: 87-96.
32. Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 2008;111: 338-43.
33. Matesanz-Isabel J, Sintes J, Llinas L, de Salort J, Lazaro A, Engel P. New B-cell CD molecules. Immunol Lett 2011;134: 104-12.
34. Nagata S, Ise T, Pastan I. Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells. J Immunol 2009;182: 7518-26.
35. Vidal-Laliena M, Romero X, March S, Requena V, Petriz J, Engel P. Characterization of antibodies submitted to the B cell section of the 8th Human Leukocyte Differentiation Antigens Workshop by flow cytometry and immunohistochemistry. Cell Immunol 2005; 236: 6-16.
36. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004;248: 503-18.
37. Nagata S, Onda M, Numata Y, Santora K, Beers R, Kreitman RJ, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res 2002;8: 2345-55.
38. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58: 221-37.
39. Kreitman RJ, Wilson WH, Robbins D, Margulies I, Stetler-Stevenson M, Waldmann TA, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999;94: 3340-8.
40. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18: 1622-36.
41. Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010;150: 352-8.
42. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008;111: 5334-41.
43. Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001;14: 277-89.